- Home
- BIIB vs CTRA Comparison
BIIB vs CTRA Comparison
Compare BIIB & CTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CTRA
- Stock Information
- Founded
- BIIB 1978
- CTRA 1989
- Country
- BIIB United States
- CTRA United States
- Employees
- BIIB N/A
- CTRA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CTRA Oil & Gas Production
- Sector
- BIIB Health Care
- CTRA Energy
- Exchange
- BIIB Nasdaq
- CTRA Nasdaq
- Market Cap
- BIIB 18.7B
- CTRA 18.0B
- IPO Year
- BIIB 1991
- CTRA 1990
- Fundamental
- Price
- BIIB $155.51
- CTRA $26.57
- Analyst Decision
- BIIB Buy
- CTRA Buy
- Analyst Count
- BIIB 24
- CTRA 17
- Target Price
- BIIB $174.62
- CTRA $32.65
- AVG Volume (30 Days)
- BIIB 1.6M
- CTRA 10.4M
- Earning Date
- BIIB 10-30-2025
- CTRA 11-03-2025
- Dividend Yield
- BIIB N/A
- CTRA 3.31%
- EPS Growth
- BIIB N/A
- CTRA 31.20
- EPS
- BIIB 10.97
- CTRA 2.17
- Revenue
- BIIB $10,065,900,000.00
- CTRA $6,666,000,000.00
- Revenue This Year
- BIIB $2.97
- CTRA $47.08
- Revenue Next Year
- BIIB N/A
- CTRA $7.39
- P/E Ratio
- BIIB $14.17
- CTRA $12.27
- Revenue Growth
- BIIB 4.77
- CTRA 25.92
- 52 Week Low
- BIIB $110.04
- CTRA $22.33
- 52 Week High
- BIIB $176.95
- CTRA $29.95
- Technical
- Relative Strength Index (RSI)
- BIIB 59.29
- CTRA 76.25
- Support Level
- BIIB $148.90
- CTRA $23.19
- Resistance Level
- BIIB $157.79
- CTRA $23.91
- Average True Range (ATR)
- BIIB 4.78
- CTRA 0.57
- MACD
- BIIB 0.43
- CTRA 0.37
- Stochastic Oscillator
- BIIB 82.77
- CTRA 92.62
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CTRA Coterra Energy Inc.
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.